secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001193125-22-147538
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q1 revenue up 44% to $35.1M; raises FY2022 revenue guidance
-----------------------------------------------------------------

- Revenue $35.1M, +44% YoY; installed base grew to 1,226 instruments with 116 new placements.
- GAAP net loss of $2.2M vs net income of $0.1M last year; operating loss $2.4M vs income $1.1M.
- Adjusted EBITDA $1.9M, up from $1.1M; adjusted gross margin 61% vs 60%.
- FY2022 revenue guidance raised to high end of $160M-$168M range.
- Service revenue more than doubled from prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522147538/0001193125-22-147538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312522147538/d315155d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-147538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer